Eli Lilly and Company (NYSE:LLY) Stock Position Increased by Bender Robert & Associates

Bender Robert & Associates grew its holdings in Eli Lilly and Company (NYSE:LLY) by 0.7% during the 1st quarter, Holdings Channel reports. The firm owned 18,419 shares of the company’s stock after buying an additional 136 shares during the period. Eli Lilly and Company comprises approximately 3.8% of Bender Robert & Associates’ investment portfolio, making the stock its 7th biggest holding. Bender Robert & Associates’ holdings in Eli Lilly and Company were worth $15,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Shepherd Financial Partners LLC increased its position in Eli Lilly and Company by 3.8% during the 1st quarter. Shepherd Financial Partners LLC now owns 9,507 shares of the company’s stock worth $7,852,000 after purchasing an additional 350 shares in the last quarter. Hemenway Trust Co LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $4,696,000. Market Street Wealth Management Advisors LLC boosted its stake in shares of Eli Lilly and Company by 3.7% during the 1st quarter. Market Street Wealth Management Advisors LLC now owns 15,859 shares of the company’s stock worth $13,098,000 after purchasing an additional 571 shares during the last quarter. GSB Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 6.8% during the first quarter. GSB Wealth Management LLC now owns 876 shares of the company’s stock worth $723,000 after buying an additional 56 shares in the last quarter. Finally, Optivise Advisory Services LLC raised its position in shares of Eli Lilly and Company by 1.6% in the first quarter. Optivise Advisory Services LLC now owns 2,023 shares of the company’s stock valued at $1,671,000 after buying an additional 32 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $791.61 on Wednesday. The firm’s fifty day simple moving average is $777.90 and its 200 day simple moving average is $801.70. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The firm has a market capitalization of $750.24 billion, a price-to-earnings ratio of 64.41, a PEG ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same period last year, the business earned $2.58 earnings per share. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Erste Group Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, June 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.